Allos Therapeutics' (ALTH) Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that the European Medicines Agency (EMEA), with a positive opinion of the Committee for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
